TERUMO INTERVENTIONAL SYSTEMS

Telumo Gloabal
Ultimaster™
Ultimaster™ Tansei™
Contact
EMEA
APAC
Latin America
Clinical Evidence
CENTURY II Bifurcation sub-group
CENTURY II Multivessel disease
CENTURY II Total population
DISCOVERY 1TO3
e-Ultimaster Bifurcation sub group
e-Ultimaster Left Main sub group
e-Ultimaster Total population
MASTER DAPT
MODEL U-SES
Ultimaster™ Sirolimus Eluting Coronary Stent System

THE POWER OF n

Overview

Point1
The most studied BP-DES, over 50,000 patients world wide
Point2
The biggest real world BP-DES registry shows favorable clinical performance
Point3
The Longest history BP-DES company

The most studied BP-DES,Over 50,000 patients world wide1-2

Ultimaster has been studied worldwide by enrolling over 50,000 patients in Terumo sponsored tiral and investigator sponsored research. The clinical programs have consistently shown favorable efficacy and safety of Ultimaster even in complex lesions.

TCD-
10023PK
CENTURY CENTURY II MASTER DISCOVERY
1TO3
CENTURY
JSV
e-Ultimaster MASTER
DAPT
COLOR ULISS SCC
registry
SCAAR
Number
of patients
22 105 1123 500 60 70 37,198 4300 388 1,660 1,727 3,253
Design Single arm pharmaco kinetics Single arm,first-in-man study Randomised 1:1 vs Xience Randomised 3:1 vs BMS in patients with STEMI Single arm, patients with multivessel disease Single arm, patients requiring 2.25 mm diameter stents Single arm, all-comers, real-world use Investigator-initiated, randomised, short vs prolonged DAPT Investigator-initiated, randomised complexed large-bore radial PCI trial Single arm, all-commers, multi-center study Single arm, all-commers, single center study Multicenter registry in Sweden
Primary outcomes Sirolimus concentration in peripheral blood samples 28 days after Ultimaster implantation Late loss at 6 months Freedom from TLF at 9 months Safety at 1 month, efficacy at 6 months, safety and efficacy at 12 months OFDI strut coverage at 3 months Freedom from MACE at 9 months TLF at 1 year NACE, MACCE, MCB at 11 months (12 months post-index PCI) BARC bleeding or vascular complication related to access site TLF, TLR and composite endpoint of cardiac death, TV-MI TLR, TLF and MACE ST, Restenosis rate
Stage Published and completed Published and completed Published and completed Published and completed Published and completed Published and completed Completed and accepted for publication Enrolling, protocol published Enrolling Published and completed Published and completed Enrolling

The Biggest real-world BP-DES registry shows favorable clinical performance3

The e-Ultimaster is a single arm, real world registry enrolled over 37,198 patients. Sub-study shows Ultimaster’s favorable performance in the patient group including patients with complex lesions such as bifurcation lesion, LMT, CTO and MVD.

37,198 patients

Interim analysis presented at EuroPCR2019

e-Ultimaster registry
Study enrollment completed,Follow-up ongoing
>37,198 patients enrollede-Ultimaster registry
Study enrollment completed,Follow-up ongoing
>37,198 patients enrolled

Clinical outcomes at 1 year

Clinical outcomes at 1 yearClinical outcomes at 1 year

The Longest history BP-DES company4

Terumo launched world’s first biodegradable polymer DES in 2008. Ultimaster is terumo’s secound BP-DES with a thin-strut flexible design contributing to long term patency developed by new biodegradable polymer technology.

2008 Nobori The world’s first biodegradable polymer drug eluting stent 2011 Orsiro Biotronik 2012 Synergy Boston scientific 2014 Ultimaster2008 Nobori The world’s first biodegradable polymer drug eluting stent 2011 Orsiro Biotronik 2012 Synergy Boston scientific 2014 Ultimaster

Reference

Customer support

At TERUMO, we don´t just deliver quality medical products – we offer the resources and support necessary for them to be used to their full potential. Contact us today for any assistance you may need.